

# Mindfulness meditation on blood pressure and quality of life in patients with intradialytic hypertension

<b>Submission date</b> 23/10/2024	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 29/10/2024	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 23/09/2025	<b>Condition category</b> Circulatory System	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

### Background and study aims

This study aims to observe the effects of mindfulness meditation on blood pressure changes and quality of life in hypertensive patients suffering from intradialytic hypertension (IDH) during hemodialysis.

### Who can participate?

Patients aged 18 years or older with maintenance hemodialysis and IDH

### What does the study involve?

The control group received routine care (hemodialysis and health education), while the intervention group received mindfulness meditation in addition to routine care. Blood pressure and quality of life changes were evaluated at enrollment and three months post-intervention.

### What are the possible benefits and risks of participating?

Mindfulness meditation may improve blood pressure during dialysis and enhance patients' quality of life.

The intervention group may experience inauthentic self-perceptions and increased sensory perceptual sensitivity.

### Where is the study run from?

Blood Purification Center of Lihuili Hospital in Ningbo City

### When is the study starting and how long is it expected to run for?

May 2023 to November 2023

### Who is funding the study?

Investigator initiated and funded

### Who is the main contact?

Jiang Liu, [liujiang\\_2024@126.com](mailto:liujiang_2024@126.com)

# Contact information

## Type(s)

Public, Scientific, Principal investigator

## Contact name

Dr Jiang Liu

## Contact details

No. 1111, Jiangnan Road, Yinzhou District

Ningbo

China

315099

+86 13429286446

liujiang\_2024@126.com

# Additional identifiers

## Clinical Trials Information System (CTIS)

Nil known

## ClinicalTrials.gov (NCT)

Nil known

## Protocol serial number

Nil known

# Study information

## Scientific Title

Mindfulness meditation on blood pressure and quality of life in patients with intradialytic hypertension during hemodialysis

## Study objectives

Mindfulness meditation may improve blood pressure during dialysis and enhance patients' quality of life.

## Ethics approval required

Ethics approval required

## Ethics approval(s)

approved 14/08/2023, Ethics Review Committee of Lihuili Hospital in Ningbo City (No. 57, Xingning Road, Yinzhou District, Ningbo, 315040, China; +86 0574 87018834; lihuiliethics@163.com), ref: KY2023PJ204

## Study design

Single-center interventional double-blind randomized controlled trial

## Primary study design

Interventional

## **Study type(s)**

Quality of life, Treatment

## **Health condition(s) or problem(s) studied**

Blood pressure control and recovery in hemodialysis patients

## **Interventions**

The patients are randomly assigned to an intervention group and a control group using a random number table. The control group received standard antihypertensive drug treatment and routine care (including hemodialysis and health education), while the intervention group additionally received mindfulness meditation intervention.

The intervention was 3 times a week, about 63 minutes each time, for a total of 12 weeks, including: 1.Observe the body (15 minutes); 2.Observe the breathing (5 minutes); 3.Dialysis visualization (5 minutes); 4.Sound wave therapy (30 minutes); 5.Stress release (8 minutes), a total of 5 parts (total 63 minutes).

After the intervention, the subjects' experiences and problems encountered during meditation are discussed in the group through the WeChat platform, and medical staff will provide relevant answers and guidance.

## **Intervention Type**

Behavioural

## **Primary outcome(s)**

1. Blood pressure measured using the blood pressure monitoring module on the dialysis machine before dialysis, at 1, 2, and 3 hours during dialysis, and after dialysis
2. Quality of life measured using the Kidney Disease and Treatment-related Quality of Life (KDTA) and the general health-related quality of life (SF-36) scales before and 12 weeks after the intervention

## **Key secondary outcome(s))**

Fasting venous blood was collected from the elbow to measure hemoglobin (Hb), inflammation markers (IL-6, CRP), nutritional indicators (ALB), homocysteine (Hcy), Parathyroid hormone (PTH) and dialysis adequacy (KT/V) before and 12 weeks after the intervention.

1. Hb measured using advanced photoelectric detector
2. CRP measured using chemiluminescence
3. IL-6 measured using enzyme-linked immunosorbent assay (ELISA).
4. ALB measured using ultraviolet spectrophotometer
5. HCY measured using radioenzyme assay
6. PTH measured using fluorescent immunochromatography

## **Completion date**

16/11/2023

## **Eligibility**

### **Key inclusion criteria**

1. Meeting the diagnostic criteria for hypertension during dialysis, that is, the blood pressure increased by more than 15 mmHg during dialysis
2. Aged between 18 and 75 years old, with good overall health status
3. Demonstrating good treatment compliance and being able to actively cooperate with the doctor's treatment and guidance
4. The weekly dialysis time was 9 - 12 hours, the KT/V value was at least 1.2, and the hemoglobin (Hb) level was between 10 - 13 g/dL
5. Being able to accurately measure blood pressure in the upper limbs

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Mixed

**Lower age limit**

18 years

**Upper age limit**

75 years

**Sex**

All

**Total final enrolment**

69

**Key exclusion criteria**

1. Patients whose blood pressure could only be measured in the lower limbs
2. Patients with mental disorders or other diseases that affected their cooperation in the study
3. Patients with other serious diseases that might affect the study results

**Date of first enrolment**

02/07/2023

**Date of final enrolment**

14/08/2023

**Locations****Countries of recruitment**

China

**Study participating centre**

Ningbo Medical Center Li Huili Hospital  
No. 1111, Jiangnan Road, Yinzhou District

Ningbo  
China  
315099

## Sponsor information

**Organisation**  
Ningbo Medical Center Lihuili Hospital

**ROR**  
<https://ror.org/030zcqn97>

## Funder(s)

**Funder type**  
Other

**Funder Name**  
Investigator funded and initiated

## Results and Publications

**Individual participant data (IPD) sharing plan**  
The datasets generated during and/or analysed during the current study are/will be available upon request from the corresponding author, Jiang Liu, [liujiang\\_2024@126.com](mailto:liujiang_2024@126.com).

**IPD sharing plan summary**  
Available on request

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>		16/09/2025	23/09/2025	Yes	No
<a href="#">Participant information sheet</a>	Participant information sheet	11/11/2025	11/11/2025	No	Yes